Status: Not yet recruiting
Efficacy and Safety of Fruquintinib Combined With Sintilimab and Stereotactic Body Radiation Therapy (SBRT) for the Second-line and Higher-line Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma With Oligometastatic Progression
Efficacy and safety of fruquintinib in combination with sintilizumab and SBRT in the treatment of oligonadenocarcinoma progression in the stomach or gastroesophageal junction
Participants needed: 30
Trial details
Phase: Phase 2, Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Queling LiuUpdated: May 16, 2025
Eligibility criteria
Have fully understood this study and voluntarily signed the informed consent for... [+5]
Have previously received treatment with VEGF or VEGFR inhibitors; [+16]